You are here: Industry Insights > neurodegenerative disease

News List

CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders firstwordpharma
July 30, 2021
CytRx Corporation (OTCQB: CYTR) today announced that based on results from its 2021 Annual Meeting of Stockholders (the "Annual Meeting"), both of the Company's Class III director candidates have been elected to the Board of Directors (the "Board").
Insilico enters into a collaboration with APRINOIA to apply novel generative AI-powered system to discover novel compounds for neurodegenerative diseases prnasia
December 30, 2020
Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico's novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation ...
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases prnasia
November 17, 2020
Alterity Therapeutics has announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).
CuraSen doses first subjects in phase 1 trial of CST-2032 pharmaceutical-business-review
September 18, 2020
CuraSen Therapeutics announced that it has dosed its first subjects in a multi-part, Phase 1 clinical study with CST-2032, the company’s first proprietary compound intended for the treatment of neurodegenerative disease.
Clinigen's ALS therapy bags US orphan status pharmatimes
July 14, 2020
ALS is a severe, neurodegenerative disease which affects motor neurons leading to progressive muscle weakness, paralysis and ultimately death within a median time of two to four years from disease onset.
Yumanity Therapeutics signs drug development deal with Merck pharmaceutical-technology
June 28, 2020
US-based Yumanity Therapeutics has signed a research collaboration and licence agreement with Merck (MSD) to develop new therapies for neurodegenerative diseases.
Statins could protect against motor neurone disease, scientists suggest pharmaphorum
February 18, 2019
High cholesterol could be a risk factor in development of motor neurone disease, according to a study of genetic data by UK scientists.
Compensating for loss of neurodegenerative disease gene ATM offers insights into cancer drug resistance firstwordpharma
January 09, 2019
Mutations in the ATM gene cause the devastating neurodegenerative and cancer predisposition disease called ataxia-telangiectasia (A-T), and are also associated with various forms of sporadic cancer.
Vect-Horus, Amgen, Bristol-Myers Squibb pharmaceutical-technology
December 17, 2018
Vect-Horus has signed a research agreement with Janssen Pharmaceuticals for the development of neurodegenerative disease treatments.....
Vect-Horus and Janssen partner for neurodegenerative disease treatment SHARE pharmaceutical-technology
December 13, 2018
Vect-Horus has entered a research collaboration agreement with Johnson & Johnson subsidiary Janssen Pharmaceuticals for treating neurodegenerative diseases.....

Previous page 1 2 Next page